8-K: Kairos Pharma Awards $1.17M in Executive Compensation

Kairos Pharma's Compensation Committee approved $950,000 in restricted stock units and $227,500 in cash bonuses for executive officers and directors for their service.

Summary

• The Compensation Committee of Kairos Pharma, Ltd. approved the grant of an aggregate of $950,000 in restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan.
• RSUs were granted to certain executive officers and directors for their service from October 2025 to October 2026, calculated based on a per share price of $1.31.
• Executive officers also received cash bonuses totaling $227,500 in recognition of their performance for the fiscal year 2024.
• John S. Yu (CEO, Chairman) received 190,840 RSUs ($250,000) and a $87,500 cash bonus.
• Neil Bhomick (CSO) received 171,756 RSUs ($225,000) and a $50,000 cash bonus.
• Ramachandran Murali (VP R&D) received 152,672 RSUs ($200,000) and a $40,000 cash bonus.
• Doug Samuelson (CFO) received 152,672 RSUs ($200,000) and a $50,000 cash bonus.
• Independent directors Hyun W. Bae, Hansoo Michael Keyoung, and Rahul Singhvi each received 19,084 RSUs ($25,000 each).
• The RSUs will vest in full on October 8, 2026, subject to continuous service, with accelerated vesting upon a change in control of the company.

Sentiment

Score: 6

Explanation: The filing details routine executive compensation, which is a neutral event. It reflects standard corporate governance practices for incentivizing and retaining key personnel, without indicating significant positive or negative operational or financial performance changes.

Positives

• The grants serve as an incentive for executive officers and directors, aligning their interests with long-term shareholder value.
• Cash bonuses recognize and reward executive performance for fiscal year 2024.
• The compensation package aims to retain key talent crucial for the company's strategic objectives and operations.

Negatives

• The issuance of restricted stock units will result in future dilution for existing shareholders upon vesting.
• The aggregate compensation package represents a significant expense for the company, totaling $1,177,500 ($950,000 in RSUs and $227,500 in cash bonuses).

Risks

• Unvested RSUs are subject to forfeiture if the recipient's service with the company terminates for cause or voluntarily prior to the vesting date.
• RSUs cannot be exercised, sold, pledged, or otherwise transferred until they become vested.
• Resale of shares received upon RSU vesting will be subject to applicable federal and state securities laws and regulations.

Future Outlook

The Restricted Stock Units are scheduled to vest in full on October 8, 2026, contingent on the recipients' continuous service. In the event of a change in control of the company prior to this date, all unvested RSUs will become fully vested immediately.

Management Comments

• The Compensation Committee approved these grants to recognize performance and incentivize continued service from executive officers and directors.

Industry Context

The granting of restricted stock units and cash bonuses is a standard practice in the biopharmaceutical industry to attract, retain, and motivate key executive talent. Such compensation structures are designed to align management's long-term interests with those of shareholders, particularly in a sector characterized by long development cycles and high-risk, high-reward ventures.

Comparison to Industry Standards

• The use of a combination of equity (RSUs) and cash bonuses for executive and director compensation is a common practice across the biopharma industry, aiming to balance short-term performance recognition with long-term value creation.
• Specific benchmarks for compensation amounts relative to comparable companies or projects are not provided within this filing, making a direct quantitative comparison difficult without external industry data.

Related Party Transactions

• Compensation grants, including $950,000 in Restricted Stock Units and $227,500 in cash bonuses, were approved for executive officers and directors, who are considered related parties to the company.

Stakeholder Impact

• Shareholders: Potential future dilution from the issuance of common stock upon RSU vesting, but also potential benefit from incentivized management performance.
• Executive Officers and Directors: Direct financial benefit through equity grants and cash bonuses, intended to enhance retention and motivation.

Next Steps

• Recipients will continue their service to the company through the RSU vesting date of October 8, 2026.
• The company will issue common stock to RSU recipients upon vesting, subject to the terms of the 2023 Equity Incentive Plan and individual grant agreements.

Key Dates

Recommendation

The filing details routine executive and director compensation, including restricted stock units and cash bonuses. While these incentives aim to align management interests with shareholders and retain key talent, they do not present new information that would fundamentally alter the company's investment profile or warrant a change in investment recommendation based solely on this filing.

Keywords

Kairos Pharma, KAPA, Executive Compensation, Restricted Stock Units, RSU, Cash Bonus, Equity Incentive Plan, Corporate Governance, Biopharma, Pharmaceuticals, SEC Filing, 8-K